144 related articles for article (PubMed ID: 31017898)
1. Use of PTC124 for nonsense suppression therapy targeting BMP4 nonsense variants in vitro and the bmp4st72 allele in zebrafish.
Krall M; Htun S; Slavotinek A
PLoS One; 2019; 14(4):e0212121. PubMed ID: 31017898
[TBL] [Abstract][Full Text] [Related]
2. Functional rescue of REP1 following treatment with PTC124 and novel derivative PTC-414 in human choroideremia fibroblasts and the nonsense-mediated zebrafish model.
Moosajee M; Tracey-White D; Smart M; Weetall M; Torriano S; Kalatzis V; da Cruz L; Coffey P; Webster AR; Welch E
Hum Mol Genet; 2016 Aug; 25(16):3416-3431. PubMed ID: 27329764
[TBL] [Abstract][Full Text] [Related]
3. Aminoglycosides, but not PTC124 (Ataluren), rescue nonsense mutations in the leptin receptor and in luciferase reporter genes.
Bolze F; Mocek S; Zimmermann A; Klingenspor M
Sci Rep; 2017 Apr; 7(1):1020. PubMed ID: 28432296
[TBL] [Abstract][Full Text] [Related]
4. PTC124 is an orally bioavailable compound that promotes suppression of the human CFTR-G542X nonsense allele in a CF mouse model.
Du M; Liu X; Welch EM; Hirawat S; Peltz SW; Bedwell DM
Proc Natl Acad Sci U S A; 2008 Feb; 105(6):2064-9. PubMed ID: 18272502
[TBL] [Abstract][Full Text] [Related]
5. Read-through strategies for suppression of nonsense mutations in Duchenne/ Becker muscular dystrophy: aminoglycosides and ataluren (PTC124).
Finkel RS
J Child Neurol; 2010 Sep; 25(9):1158-64. PubMed ID: 20519671
[TBL] [Abstract][Full Text] [Related]
6. Muscle dysfunction and structural defects of dystrophin-null sapje mutant zebrafish larvae are rescued by ataluren treatment.
Li M; Andersson-Lendahl M; Sejersen T; Arner A
FASEB J; 2014 Apr; 28(4):1593-9. PubMed ID: 24371125
[TBL] [Abstract][Full Text] [Related]
7. A lack of premature termination codon read-through efficacy of PTC124 (Ataluren) in a diverse array of reporter assays.
McElroy SP; Nomura T; Torrie LS; Warbrick E; Gartner U; Wood G; McLean WH
PLoS Biol; 2013; 11(6):e1001593. PubMed ID: 23824517
[TBL] [Abstract][Full Text] [Related]
8. Translational Read-Through Therapy of
Vössing C; Owczarek-Lipska M; Nagel-Wolfrum K; Reiff C; Jüschke C; Neidhardt J
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33182541
[TBL] [Abstract][Full Text] [Related]
9. Premature termination codon read-through in the ABCC6 gene: potential treatment for pseudoxanthoma elasticum.
Zhou Y; Jiang Q; Takahagi S; Shao C; Uitto J
J Invest Dermatol; 2013 Dec; 133(12):2672-2677. PubMed ID: 23702584
[TBL] [Abstract][Full Text] [Related]
10. Rescue of melanocortin 4 receptor (MC4R) nonsense mutations by aminoglycoside-mediated read-through.
Brumm H; Mühlhaus J; Bolze F; Scherag S; Hinney A; Hebebrand J; Wiegand S; Klingenspor M; Grüters A; Krude H; Biebermann H
Obesity (Silver Spring); 2012 May; 20(5):1074-81. PubMed ID: 21738238
[TBL] [Abstract][Full Text] [Related]
11. Comparison of read-through effects of aminoglycosides and PTC124 on rescuing nonsense mutations of HERG gene associated with long QT syndrome.
Yu H; Liu X; Huang J; Zhang Y; Hu R; Pu J
Int J Mol Med; 2014 Mar; 33(3):729-35. PubMed ID: 24366185
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of premature stop codon readthrough in the CFTR gene by Ataluren (PTC124) derivatives.
Pibiri I; Lentini L; Melfi R; Gallucci G; Pace A; Spinello A; Barone G; Di Leonardo A
Eur J Med Chem; 2015 Aug; 101():236-44. PubMed ID: 26142488
[TBL] [Abstract][Full Text] [Related]
13. Exploring the readthrough of nonsense mutations by non-acidic Ataluren analogues selected by ligand-based virtual screening.
Pibiri I; Lentini L; Tutone M; Melfi R; Pace A; Di Leonardo A
Eur J Med Chem; 2016 Oct; 122():429-435. PubMed ID: 27404557
[TBL] [Abstract][Full Text] [Related]
14. Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosis.
Sermet-Gaudelus I; Boeck KD; Casimir GJ; Vermeulen F; Leal T; Mogenet A; Roussel D; Fritsch J; Hanssens L; Hirawat S; Miller NL; Constantine S; Reha A; Ajayi T; Elfring GL; Miller LL
Am J Respir Crit Care Med; 2010 Nov; 182(10):1262-72. PubMed ID: 20622033
[TBL] [Abstract][Full Text] [Related]
15. Nonsense suppressor therapies rescue peroxisome lipid metabolism and assembly in cells from patients with specific PEX gene mutations.
Dranchak PK; Di Pietro E; Snowden A; Oesch N; Braverman NE; Steinberg SJ; Hacia JG
J Cell Biochem; 2011 May; 112(5):1250-8. PubMed ID: 21465523
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial.
Kerem E; Hirawat S; Armoni S; Yaakov Y; Shoseyov D; Cohen M; Nissim-Rafinia M; Blau H; Rivlin J; Aviram M; Elfring GL; Northcutt VJ; Miller LL; Kerem B; Wilschanski M
Lancet; 2008 Aug; 372(9640):719-27. PubMed ID: 18722008
[TBL] [Abstract][Full Text] [Related]
17. Membrane blebbing as an assessment of functional rescue of dysferlin-deficient human myotubes via nonsense suppression.
Wang B; Yang Z; Brisson BK; Feng H; Zhang Z; Welch EM; Peltz SW; Barton ER; Brown RH; Sweeney HL
J Appl Physiol (1985); 2010 Sep; 109(3):901-5. PubMed ID: 20558759
[TBL] [Abstract][Full Text] [Related]
18. The effect of PTC124 on choroideremia fibroblasts and iPSC-derived RPE raises considerations for therapy.
Torriano S; Erkilic N; Baux D; Cereso N; De Luca V; Meunier I; Moosajee M; Roux AF; Hamel CP; Kalatzis V
Sci Rep; 2018 May; 8(1):8234. PubMed ID: 29844446
[TBL] [Abstract][Full Text] [Related]
19. PTC124 targets genetic disorders caused by nonsense mutations.
Welch EM; Barton ER; Zhuo J; Tomizawa Y; Friesen WJ; Trifillis P; Paushkin S; Patel M; Trotta CR; Hwang S; Wilde RG; Karp G; Takasugi J; Chen G; Jones S; Ren H; Moon YC; Corson D; Turpoff AA; Campbell JA; Conn MM; Khan A; Almstead NG; Hedrick J; Mollin A; Risher N; Weetall M; Yeh S; Branstrom AA; Colacino JM; Babiak J; Ju WD; Hirawat S; Northcutt VJ; Miller LL; Spatrick P; He F; Kawana M; Feng H; Jacobson A; Peltz SW; Sweeney HL
Nature; 2007 May; 447(7140):87-91. PubMed ID: 17450125
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic Suppression of Nonsense Mutation: An Emerging Target in Multiple Diseases and Thrombotic Disorders.
Asiful Islam M; Alam F; Kamal MA; Gan SH; Wong KK; Sasongko TH
Curr Pharm Des; 2017; 23(11):1598-1609. PubMed ID: 27875971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
